Analysis Group to Present HEOR Research at ASCO Genitourinary Cancers Symposium
Event:ASCO Genitourinary Cancers Symposium
Dates:
February 26–28, 2026
Host:
American Society of Clinical Oncology (ASCO)
Location:
San Francisco, CA
Researchers from Analysis Group’s HEOR, Epidemiology & Market Access practice will present six posters at the American Society of Clinical Oncology’s (ASCO’s) annual Genitourinary Cancers Symposium, which will be held February 26–28, 2026, in San Francisco, CA.
The firm’s poster presentations will include:
Poster Session A: Prostate Cancer – February 26
- Abstract 338: “Patient (pt) preferences for treatment (tx) of non-metastatic hormone-sensitive prostate cancer (nmHSPC): A discrete choice experiment (DCE),” coauthored by an Analysis Group team – including Managing Principal Hongbo Yang, Vice President Weiguang Xue, and Manager Yan Meng – in collaboration with researchers from START Carolinas/Carolina Urologic Research Center, University Hospital Schleswig-Holstein, and Astellas Pharma.
This study was sponsored by Astellas Pharma.
- Abstract 106: “Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professionals Alessio Palladino and Gordon Wong – in collaboration with researchers from Chesapeake Urology, New Jersey Urology, the Winship Cancer Institute of Emory University, and Johnson & Johnson.
This study was sponsored by Johnson & Johnson.
- Abstract 343: “Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP),” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professionals Francesca Lee, Yuxi Wang, and Gordon Wong – in collaboration with researchers from Advent Health Urology, Chesapeake Urology, New Jersey Urology, START Carolinas/Carolina Urologic Research Center, and Johnson & Johnson.
This study was sponsored by Johnson & Johnson.
- Abstract 180: “Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castration sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data,” coauthored by an Analysis Group team – including Managing Principals Maral DerSarkissian and Mei Sheng Duh, Vice President Priyanka Bobbili, and Associate Naiyu Chen – in collaboration with researchers from the Dana-Farber Cancer Institute, Astellas Pharma, and Pfizer.
This study was sponsored by Astellas Pharma and Pfizer.
Poster Session B: Prostate Cancer and Urothelial Carcinoma – February 27
- Abstract 709: “Quality of care (QoC) measures among patients with recurrent, papillary-only Bacillus Calmette-Guérin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC),” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Managers Rebecca Bungay and Carmine Rossi, and Senior Analyst Steven Liu – in collaboration with researchers from the Stanford University School of Medicine, Medstar Georgetown University Hospital, and Johnson & Johnson.
This study was sponsored by Johnson & Johnson.
- Abstract 708: “Front-line (1L) treatment and recurrence patterns among patients with high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following Bacillus Calmette-Guérin (BCG) or other intravesical therapies (IVT),” coauthored by an Analysis Group team – including Vice Presidents Bruno Émond and Dominic Pilon, Managers Rebecca Bungay and Carmine Rossi, and Senior Analyst Steven Liu – in collaboration with researchers from the Stanford University School of Medicine, Medstar Georgetown University Hospital, and Johnson & Johnson.
This study was sponsored by Johnson & Johnson.